Semaglutide for high blood sugar after kidney transplant
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be willing to sign consent and follow the trial plan
- Be age 18 to 80
- Have high blood sugar 10 to 40 days after your kidney transplant (or had type 2 diabetes before the transplant and were on glucose-lowering medicine)
- Have enough kidney function soon after transplant (eGFR greater than 15)
- Not have type 1 diabetes, and not currently be on dialysis
- Agree to avoid certain diabetes medicines right before screening (no DPP-4 inhibitors in the last 5 days, and no GLP-1 medicines like semaglutide within 10 days)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two different medicines (empagliflozin or semaglutide) added to your usual insulin to see if they help with blood sugar control and weight loss in people with type 1 diabetes who are overweight or have obesity. It may be a good fit if your diabetes is not well controlled with insulin injections alone.
This trial tests whether semaglutide (a diabetes drug) can help protect kidney function in people with type 2 diabetes who already have mild to moderate kidney damage. You will take semaglutide or a placebo and have regular kidney function tests.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
This trial tests whether a medication called an SGLT2 inhibitor can help prevent new-onset diabetes after a kidney transplant. It is for people who have received a kidney transplant, do not have diabetes, and are taking tacrolimus.
This trial tests if the drug semaglutide can prevent the development of diabetes in people who have recently had a kidney transplant. It may help those at higher risk for post-transplant diabetes.
This study tests if an oral semaglutide pill can reduce liver fat and improve body composition in people who have had a liver transplant and have diabetes. It may help manage weight and blood sugar after transplant.
Hear when a new Hyperglycemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.